Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.

Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L, Vozenin MC.

Front Oncol. 2018 Dec 12;8:609. doi: 10.3389/fonc.2018.00609. eCollection 2018. Review.

2.

Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?

Martin Lluesma S, Graciotti M, Chiang CL, Kandalaft LE.

Vaccines (Basel). 2018 Nov 23;6(4). pii: E79. doi: 10.3390/vaccines6040079. Review.

3.

Cancer Vaccines in Ovarian Cancer: How Can We Improve?

Martin Lluesma S, Wolfer A, Harari A, Kandalaft LE.

Biomedicines. 2016 May 3;4(2). pii: E10. doi: 10.3390/biomedicines4020010. Review.

4.

Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1.

Martin-Lluesma S, Schaeffer C, Robert EI, van Breugel PC, Leupin O, Hantz O, Strubin M.

Hepatology. 2008 Nov;48(5):1467-76. doi: 10.1002/hep.22542.

PMID:
18781669
5.

Recombinant antibodies against subcellular fractions used to track endogenous Golgi protein dynamics in vivo.

Nizak C, Martin-Lluesma S, Moutel S, Roux A, Kreis TE, Goud B, Perez F.

Traffic. 2003 Nov;4(11):739-53.

6.

Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2.

Martin-Lluesma S, Stucke VM, Nigg EA.

Science. 2002 Sep 27;297(5590):2267-70.

Supplemental Content

Loading ...
Support Center